ALXO (ALX Oncology Holdings Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by ALXO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-18 | Jason Lettmann | CHIEF EXECUTIVE OFFICER | Sell | — | — |
| 2026-08-18 | Shelly Wong | SVP, FINANCE AND CAO | Sell | — | — |
| 2026-07-06 | Shelly Wong | SVP, FINANCE AND CAO | Sell | — | — |
| 2026-04-17 | Jeff E. Knight | Chief Dev & Operating Officer | A | — | — |
| 2026-04-17 | Barbara Klencke | Chief Medical Officer | A | — | — |
| 2026-03-23 | Shelly Pinto | SVP, FINANCE AND CAO | Sell | — | — |
| 2026-03-23 | Jason Lettmann | CHIEF EXECUTIVE OFFICER | Sell | — | — |
| 2026-03-05 | Barbara Klencke | Chief Medical Officer | A | — | — |
| 2026-02-20 | Shelly Pinto | SVP, FINANCE AND CAO | Sell | — | — |
| 2026-02-19 | Jason Lettmann | CHIEF EXECUTIVE OFFICER | F | — | — |
| 2026-02-04 | COREY S GOODMAN | Director | Buy | — | — |
| 2026-01-28 | Jason Lettmann | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2026-01-28 | Harish Shantharam | Chief Financial Officer | A | — | — |
| 2026-01-28 | Shelly Pinto | SVP, FINANCE AND CAO | A | — | — |
| 2026-01-21 | Rekha Hemrajani | Director | A | — | — |
| 2026-01-21 | Alan B. Sandler | Director | A | — | — |
| 2026-01-21 | J. Scott Garland | Director | A | — | — |
| 2026-01-21 | Daniel J. Curran | Director | A | — | — |
| 2026-01-21 | COREY S GOODMAN | Director | A | — | — |
| 2026-01-21 | Chris H Takimoto | Director | A | — | — |
| 2026-01-07 | Shelly Pinto | SVP, FINANCE AND CAO | Sell | — | — |
| 2025-10-16 | Harish Shantharam | Chief Financial Officer | A | — | — |
| 2025-10-16 | Shelly Pinto | SVP, FINANCE AND CAO | A | — | — |
| 2025-10-16 | Jason Lettmann | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2025-09-19 | Barbara Klencke | Director | A | — | — |
| 2025-09-18 | Jason Lettmann | CHIEF EXECUTIVE OFFICER | Buy | — | — |
| 2025-08-20 | Harish Shantharam | Chief Financial Officer | Buy | — | — |
| 2025-08-19 | Jason Lettmann | CHIEF EXECUTIVE OFFICER | Sell | — | — |
| 2025-08-19 | Shelly Pinto | SVP, FINANCE AND CAO | Sell | — | — |
| 2025-08-13 | Daniel J. Curran | Director | A | — | — |
| 2025-07-08 | Shelly Pinto | SVP, FINANCE AND CAO | Sell | — | — |
| 2025-07-01 | Shelly Pinto | SVP, FINANCE AND CAO | Sell | — | — |
| 2025-04-15 | Harish Shantharam | Chief Financial Officer | A | — | — |
| 2025-04-15 | Alan B. Sandler | Chief Medical Officer | A | — | — |
| 2025-04-15 | Shelly Pinto | SVP, FINANCE AND CAO | A | — | — |
| 2025-04-15 | Jason Lettmann | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2025-03-18 | Jason Lettmann | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2025-03-18 | Shelly Pinto | SVP, FINANCE AND CAO | A | — | — |
| 2025-02-21 | Jaume Pons | PRESIDENT & CSO | Sell | — | — |
| 2025-02-21 | Shelly Pinto | SVP, FINANCE AND CAO | Sell | — | — |
| 2025-02-21 | Jason Lettmann | CHIEF EXECUTIVE OFFICER | Sell | — | — |
| 2025-01-23 | Chris H Takimoto | Director | A | — | — |
| 2025-01-23 | Alan B. Sandler | Chief Medical Officer | A | — | — |
| 2025-01-23 | Jason Lettmann | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2025-01-23 | J. Scott Garland | Director | A | — | — |
| 2025-01-23 | COREY S GOODMAN | Director | A | — | — |
| 2025-01-23 | Shelly Pinto | SVP, FINANCE AND CAO | A | — | — |
| 2025-01-23 | Barbara Klencke | Director | A | — | — |
| 2025-01-23 | Rekha Hemrajani | Director | A | — | — |
| 2025-01-23 | Harish Shantharam | Chief Financial Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 4,066,195 | — |
| — | CHIEF EXECUTIVE OFFICER | 2,317,848 | — |
| — | 10%+ Owner | 2,097,326 | — |
| — | Director | 995,000 | — |
| — | PRESIDENT & CSO | 579,388 | — |
| — | CHIEF MEDICAL OFFICER | 325,711 | — |
| — | 10%+ Owner | 309,222 | — |
| — | 10%+ Owner | 185,526 | — |
| — | CHIEF FINANCIAL OFFICER | 121,516 | — |
| — | 10%+ Owner | 120,212 | — |
| — | Director | 113,287 | — |
| — | SVP, FINANCE AND CAO | 87,828 | — |
| — | Chief Financial Officer | 75,000 | — |
| — | Director | 33,000 | — |
| — | Chief Business Officer | 11,254 | — |
| — | VP Fin & Chief Acct Officer | 3,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ALXO quote page; the site-wide leaderboard is on the insider transactions hub.